Final Analysis of a Trial of M72/AS01E Vaccine to Prevent Tuberculosis. by Tait, Dereck R et al.
Th e  n e w  e ngl a nd  j o u r na l  o f  m e dic i n e
n engl j med nejm.org 1
The authors’ full names, academic de-
grees, and affiliations are listed in the 
Appendix. Address reprint requests to 
Dr. Van Der Meeren at GlaxoSmithKline, 
20 Fleming Ave., 1300 Wavre, Belgium, 
or at  olivier . x . van-der-meeren@ gsk . com.
Drs. Tait and Hatherill and Drs. Wilkinson 
and Roman contributed equally to this 
article.
This article was published on October 29, 
2019, at NEJM.org.
DOI: 10.1056/NEJMoa1909953
Copyright © 2019 Massachusetts Medical Society.
BACKGROUND
Results of an earlier analysis of a trial of the M72/AS01E candidate vaccine against Myco-
bacterium tuberculosis showed that in infected adults, the vaccine provided 54.0% protection 
against active pulmonary tuberculosis disease, without evident safety concerns. We now 
report the results of the 3-year final analysis of efficacy, safety, and immunogenicity.
METHODS
From August 2014 through November 2015, we enrolled adults 18 to 50 years of age 
with M. tuberculosis infection (defined by positive results on interferon-γ release assay) 
without evidence of active tuberculosis disease at centers in Kenya, South Africa, and 
Zambia. Participants were randomly assigned in a 1:1 ratio to receive two doses of either 
M72/AS01E or placebo, administered 1 month apart. The primary objective was to 
evaluate the efficacy of M72/AS01E to prevent active pulmonary tuberculosis disease 
according to the first case definition (bacteriologically confirmed pulmonary tubercu-
losis not associated with human immunodeficiency virus infection). Participants were 
followed for 3 years after the second dose. Participants with clinical suspicion of tuber-
culosis provided sputum samples for polymerase-chain-reaction assay, mycobacterial 
culture, or both. Humoral and cell-mediated immune responses were evaluated until 
month 36 in a subgroup of 300 participants. Safety was assessed in all participants who 
received at least one dose of M72/AS01E or placebo.
RESULTS
A total of 3575 participants underwent randomization, of whom 3573 received at least 
one dose of M72/AS01E or placebo, and 3330 received both planned doses. Among the 
3289 participants in the according-to-protocol efficacy cohort, 13 of the 1626 partici-
pants in the M72/AS01E group, as compared with 26 of the 1663 participants in the 
placebo group, had cases of tuberculosis that met the first case definition (incidence, 
0.3 vs. 0.6 cases per 100 person-years). The vaccine efficacy at month 36 was 49.7% 
(90% confidence interval [CI], 12.1 to 71.2; 95% CI, 2.1 to 74.2). Among participants in 
the M72/AS01E group, the concentrations of M72-specific antibodies and the frequen-
cies of M72-specific CD4+ T cells increased after the first dose and were sustained 
throughout the follow-up period. Serious adverse events, potential immune-mediated 
diseases, and deaths occurred with similar frequencies in the two groups.
CONCLUSIONS
Among adults infected with M. tuberculosis, vaccination with M72/AS01E elicited an im-
mune response and provided protection against progression to pulmonary tuberculosis 
disease for at least 3 years. (Funded by GlaxoSmithKline Biologicals and Aeras; Clini-
calTrials.gov number, NCT01755598.)
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T h e  n e w  e ngl a nd  j o u r na l  o f  m e dic i n e
According to the World Health Or-ganization (WHO), tuberculosis remains the leading cause of death from a single 
pathogen globally, and safe, effective tuberculo-
sis vaccines will be key in ending the epidemic.1,2 
According to the Preferred Product Characteris-
tics published by the WHO, new tuberculosis vac-
cines for adolescents and adults with or without 
Mycobacterium tuberculosis infection should have at 
least 50% efficacy against bacteriologically con-
firmed tuberculosis, and this efficacy should be 
sustained for at least 2 (and ideally 10) years.3,4
The M72/AS01E candidate vaccine (GlaxoSmith-
Kline) contains a recombinant fusion protein de-
rived from two M. tuberculosis antigens (Mtb32A 
and Mtb39A), combined with the AS01E adjuvant 
system. A previously reported proof-of-concept, 
placebo-controlled, phase 2b trial showed effi-
cacy of two doses of M72/AS01E in preventing 
bacteriologically confirmed pulmonary tubercu-
losis in human immunodeficiency virus (HIV)–
negative adults with latent M. tuberculosis infec-
tion (defined by a positive result on interferon-γ 
release assay) who had no evidence of active tu-
berculosis disease.5 The analysis of the primary 
trial objective was performed when all partici-
pants had completed at least 2 years of follow-
up. The vaccine efficacy against bacteriologically 
confirmed active pulmonary tuberculosis (con-
firmed with the use of sputum specimens ob-
tained before the commencement of treatment 
for tuberculosis) was significant (vaccine effica-
cy, 54.0%; 90% confidence interval [CI], 13.9 to 
75.4; 95% CI, 2.9 to 78.2; P = 0.04). Injection-site 
reactions and influenza-like symptoms occurred 
more frequently in the M72/AS01E group than in 
the placebo group, but serious adverse events, 
potential immune-mediated diseases, and deaths 
occurred with similar frequencies in the two 
groups. None of the deaths were considered by 
the investigators to be related to the trial regi-
men. We now present the final results of the 
efficacy and safety analyses after 3 years of fol-
low-up and the results regarding M72-specific 
humoral and cell-mediated immunogenicity.
Me thods
Trial Design, Oversight, and Population
The trial methods have been described in detail 
previously.5 Information regarding the composi-
tion of the vaccine and the placebo is provided 
in the Supplementary Appendix and the protocol 
(both available with the full text of this article at 
NEJM.org). In brief, this double-blind, random-
ized, placebo-controlled trial was conducted in 
three African countries in which tuberculosis is 
endemic (Kenya, South Africa, and Zambia). The 
trial was conducted in accordance with the In-
ternational Conference on Harmonisation Good 
Clinical Practice guidelines and the principles of 
the Declaration of Helsinki. The protocol was 
approved by the ethics committees and regula-
tory authorities in each participating country. 
The trial was funded by GlaxoSmithKline Bio-
logicals and Aeras. Authors who are employees 
of GlaxoSmithKline and Aeras were involved in 
the conception and design of the trial and the 
collection, analysis, and interpretation of data, 
and some of them were part of the core writing 
team (see the Supplementary Appendix for a list of 
authors’ contributions). All the participants pro-
vided written or witnessed oral informed consent.
The trial population consisted of HIV-nega-
tive adults 18 to 50 years of age with M. tubercu-
losis infection, as determined by a positive result 
on interferon-γ release assay (QuantiFERON-TB 
Gold In-Tube assay [QFT, Qiagen]), who had no 
signs or symptoms of tuberculosis disease and 
who had a sputum specimen that was negative 
for M. tuberculosis on a polymerase-chain-reaction 
(PCR) assay (GeneXpert MTB/RIF, Cepheid) at 
baseline.
Objectives and Follow-up
The primary objective was to evaluate the effi-
cacy of M72/AS01E to prevent active pulmonary 
tuberculosis disease according to the first case 
definition (bacteriologically confirmed pulmo-
nary tuberculosis not associated with HIV infec-
tion and diagnosed with sputum obtained before 
initiation of treatment for tuberculosis). Cases 
that occurred from day 30 after the second dose 
of M72/AS01E or placebo until month 36 were 
included in the analyses. A secondary trial objec-
tive was to evaluate vaccine efficacy with respect 
to other case definitions: definite PCR-positive 
pulmonary tuberculosis disease not associated 
with HIV infection, diagnosed with sputum ob-
tained before initiation of tuberculosis treatment 
(second case definition); definite pulmonary tuber-
culosis disease not associated with HIV infection, 
diagnosed with sputum obtained up to 4 weeks 
after initiation of tuberculosis treatment (third 
case definition); microbiologically confirmed pul-
monary tuberculosis disease, diagnosed with 
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sputum obtained up to 4 weeks after initiation 
of tuberculosis treatment (fourth case definition); 
clinical tuberculosis (fifth case definition); and 
clinical tuberculosis not associated with HIV in-
fection (modified fifth case definition) (Table S1 
in the Supplementary Appendix). An additional 
trial objective was to assess immunogenicity. 
Data regarding secondary reactogenicity and safe-
ty objectives (including potential immune-mediat-
ed diseases and serious adverse events) recorded 
up to month 6 after the second dose were re-
ported previously5; data recorded up to month 
36 are reported here. Serious adverse events that 
were considered by the site investigators to be 
related to the trial regimen and deaths from any 
cause were recorded until the end of the follow-
up period.
Participants were followed for incident tuber-
culosis by means of visits, telephone calls, text 
messages, and participant reports for 3 years 
after the second dose of M72/AS01E or placebo. 
In some cases, when participants could not be 
contacted despite several attempts, the site staff 
also contacted close family members or friends 
to obtain new contact details and mitigate the 
risk of missing important safety information. 
Participants with clinical suspicion of pulmo-
nary tuberculosis were asked to provide three 
sputum specimens, which were collected over a 
period of 1 week, for PCR assay and liquid cul-
ture by Mycobacterial Growth Indicator Tube. 
Specimens obtained before initiation of tubercu-
losis treatment were acceptable for assessment 
of the first and second case definitions, and 
specimens obtained up to 4 weeks after initiation 
of treatment could be considered for the third 
and fourth case definitions. Treatment decisions 
were made by physicians who were not otherwise 
involved in the trial. Participants with confirmed 
tuberculosis underwent retesting for HIV, and 
their glycated hemoglobin levels were measured 
to screen for diabetes. All participants were re-
tested for HIV at the final trial visit.
Evaluation of Immunogenicity
The immunogenicity cohort included the first 
150 participants enrolled at the Kenya Medical 
Research Institute and the first 150 enrolled in 
the South African Tuberculosis Vaccine Initiative. 
Blood samples were obtained before administra-
tion of the first dose of M72/AS01E or placebo, at 
1 month after the second dose, and annually until 
year 3. The total IgG antibodies against the M72 
fusion protein were measured with the use of an 
enzyme-linked immunosorbent assay (ELISA), as 
described previously6; seropositivity was defined 
as a geometric mean concentration of anti-M72 
IgG antibodies of 2.8 or more ELISA units per 
milliliter. Cell-mediated immunity was assessed 
on the basis of M72-specific T-cell responses, 
which were evaluated with the use of a whole-
blood intracellular cytokine staining assay, as 
described previously.7 In brief, whole-blood spec-
imens were incubated for 2 hours at 37°C with a 
pool of overlapping peptides covering the M72 
protein sequence or with stimulation controls, in 
the presence of anti-CD28 and anti-CD49d anti-
bodies. A cytokine secretion inhibitor (brefeldin A) 
was added for an additional 18 hours. After red-
cell lysis and cell fixation, an intracellular cyto-
kine staining assay was used to determine CD4+ 
and CD8+ T-cell expression of CD40L, interleu-
kin-2, tumor necrosis factor α (TNF-α), and 
interferon-γ. Results are reported as the fre-
quency of CD4+ or CD8+ T cells expressing at 
least two immune markers (defined as polyposi-
tive T cells) or expressing any combination of 
markers per million CD4+ or CD8+ T cells. A 
response to the vaccine was defined as a poly-
positive T-cell frequency that was higher than 
the 95th percentile of the frequencies in all par-
ticipants before administration of the first dose.
Statistical Analysis
When the previously reported primary analysis 
was performed, the members of the trial team 
were unaware of the trial-group assignments. In 
contrast, this analysis was performed in a fully 
unblinded manner. The primary analysis of vac-
cine efficacy was performed in the according-to-
protocol efficacy cohort with the use of Cox 
proportional-hazards regression models (vaccine 
efficacy = 1 − hazard ratio), with 90% confidence 
intervals and P values for Wald tests. Descriptive 
post hoc 95% confidence intervals are also re-
ported. We used a Cox model with time-depen-
dent covariates (piecewise Cox model) to assess 
vaccine efficacy according to year of follow-up.
Efficacy was also assessed in the total effi-
cacy cohort, which consisted of all participants 
who received at least one dose of M72/AS01E or 
placebo with the exception of seven participants 
who were found to have had active tuberculosis 
disease at baseline or a medical history of active 
tuberculosis. Immunogenicity was assessed in 
the according-to-protocol immunogenicity cohort. 
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Statistical analyses were performed with SAS 
software, version 9.2 or higher, on the SAS Drug 
Development system.
R esult s
Trial Population
A total of 3575 participants underwent random-
ization; 3573 participants received at least one 
dose of M72/AS01E or placebo and were included 
in the total vaccinated cohort, and 3330 of these 
participants received both planned doses. Demo-
graphic characteristics were balanced between 
the groups (Table S2). The distribution of par-
ticipants in the cohorts and the reasons for 
withdrawal from the trial are described in Figure 
S1. HIV seroconversion occurred in 113 partici-
pants during the trial: in 61 of 1462 participants 
(4.2%; 95% CI, 3.2 to 5.3) in the M72/AS01E 
group and in 52 of 1456 participants (3.6%; 95% 
CI, 2.7 to 4.7) in the placebo group.
Vaccine Efficacy
The according-to-protocol efficacy cohort includ-
ed 3289 participants (1626 in the M72/AS01E 
group and 1663 in the placebo group). After a 
mean (±SD) follow-up of 2.7±0.4 years in the 
M72/AS01E group and 2.7±0.5 years in the placebo 
group (median, 2.8 years), 13 cases of active 
pulmonary tuberculosis in the M72/AS01E group 
and 26 cases in the placebo group met the first 
case definition (Table 1). The incidence of cases 
of pulmonary tuberculosis that met the first case 
definition was unchanged from the previous 
analysis (0.3 cases per 100 person-years in the 
M72/AS01E group and 0.6 cases per 100 person-
years in the placebo group). The overall vaccine 
efficacy at month 36 (analyzed with the use of an 
unadjusted Cox regression model) was 49.7% (90% 
CI, 12.1 to 71.2; 95% CI, 2.1 to 74.2). Kaplan–
Meier curves for the first case definition are 
shown in Figure 1. The vaccine efficacy esti-
mates according to year were 27.4% for year 1 
Figure 1. Kaplan–Meier Estimate of Definite Pulmonary Tuberculosis According to the First Case Definition.
Shown is the Kaplan–Meier estimate of the probability of freedom from tuberculosis disease according to the first 
case definition (bacteriologically confirmed pulmonary tuberculosis not associated with HIV infection, diagnosed 
before the initiation of treatment for tuberculosis). The analysis was conducted in the according-to-protocol efficacy 
cohort (3289 participants — 1626 in the M72/AS01E group and 1663 in the placebo group). The time shown is the 
time from the beginning of follow-up (i.e., 30 days after dose 2). The inset shows the same data on an enlarged y axis.
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Covariate and Group
No. of Participants/ 
Total No.†
Person-yr of  
Follow-up
Rate per 100  
Person-yr (90% CI) Vaccine Efficacy
% (90% CI) % (95% CI)
Overall
M72/AS01E 13/1626 4427.62 0.3 (0.2 to 0.5) 49.7 (12.1 to 71.2) 49.7 (2.1 to 74.2)
Placebo 26/1663 4463.06 0.6 (0.4 to 0.8)
Diabetes
No
M72/AS01E 13/1618 4407.23 0.3 (0.2 to 0.5) 49.6 (12.0 to 71.2) 49.6 (2.0 to 74.1)
Placebo 26/1658 4449.07 0.6 (0.4 to 0.8)
Yes
M72/AS01E 0/7 17.68 0 Undefined Undefined
Placebo 0/5 14.00 0
Sex
Female
M72/AS01E 7/680 1857.13 0.4 (0.2 to 0.7) 34.0 (−46.1 to 70.2) 34.0 (−70.2 to 74.4)
Placebo 11/710 1925.22 0.6 (0.3 to 0.9)
Male
M72/AS01E 6/946 2570.49 0.2 (0.1 to 0.5) 60.7 (12.9 to 82.2) 60.7 (−1.4 to 84.7)
Placebo 15/953 2537.84 0.6 (0.4 to 0.9)
Country
Kenya
M72/AS01E 2/245 675.16 0.3 (0.1 to 0.9) −100.8 (−1405.4 to 73.2) −100.8 (−2114.4 to 81.8)
Placebo 1/248 675.73 0.1 (0.0 to 0.8)
South Africa
M72/AS01E 11/1307 3548.10 0.3 (0.2 to 0.5) 53.7 (15.6 to 74.5) 53.7 (5.4 to 77.3)
Placebo 24/1344 3598.50 0.7 (0.5 to 0.9)
Zambia
M72/AS01E 0/74 204.35 0 Undefined Undefined
Placebo 1/71 188.84 0.5 (0.1 to 2.7)
Current smoker
Yes
M72/AS01E 10/831 2247.12 0.4 (0.3 to 0.7) 44.9 (−5.4 to 71.2) 44.9 (−19.4 to 74.6)
Placebo 18/844 2236.74 0.8 (0.5 to 1.2)
No
M72/AS01E 3/794 2177.78 0.1 (0.1 to 0.4) 61.7 (−16.6 to 87.4) 61.7 (−44.3 to 89.8)
Placebo 8/819 2226.32 0.4 (0.2 to 0.6)
Age
≤25 years
M72/AS01E 3/706 1911.17 0.2 (0.1 to 0.4) 81.1 (46.9 to 93.3) 81.1 (35.3 to 94.5)
Placebo 16/724 1928.26 0.8 (0.6 to 1.3)
>25 years
M72/AS01E 10/920 2516.45 0.4 (0.2 to 0.7) −0.6 (−109.9 to 51.8) −0.6 (−141.7 to 58.1)
Placebo 10/939 2534.80 0.4 (0.2 to 0.7)
≤30 years‡
M72/AS01E 9/1045 2838.94 0.3 (0.2 to 0.5) 50.0 (2.2 to 74.5) 50.0 (−11.3 to 77.5)
Placebo 18/1069 2847.15 0.6 (0.4 to 0.9)
>30 years‡
M72/AS01E 4/581 1588.68 0.3 (0.1 to 0.6) 49.0 (−39.7 to 81.4) 49.0 (−69.4 to 84.6)
Placebo 8/594 1615.91 0.5 (0.3 to 0.9)
Table 2. Vaccine Efficacy against Definite Pulmonary Tuberculosis Disease Not Associated with HIV Infection (First Case Definition).*
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(90% CI, −90.2 to 72.3; 95% CI, −128.8 to 77.0), 
55.2% for year 2 (90% CI, −20.2 to 83.3; 95% CI, 
−45.3 to 86.2), and 60.2% for year 3 (90% CI, 
−5.4 to 84.9; 95% CI, −27.0 to 87.5).
An analysis of vaccine efficacy at month 36 
that used a Cox regression model with adjustment 
for country (Kenya, South Africa, or Zambia), 
sex, diabetes status, age (≤25 or >25 years), cur-
rent smoking status (yes or no), and previous 
bacille Calmette–Guérin vaccination (yes, no, or 
unknown) yielded nearly identical results to those 
of the primary analysis (vaccine efficacy, 49.6%; 
90% CI, 11.8 to 71.02; 95% CI, 1.8 to 74.1). We 
performed a prespecified sensitivity analysis, 
described previously, that was restricted to par-
ticipants who presented with cases of tuberculo-
sis that met the first case definition and that 
were confirmed by at least two bacteriologic 
tests. The analysis included 7 participants in the 
M72/AS01E group and 22 participants in the pla-
cebo group; the vaccine efficacy was 68.0% (90% 
CI, 34.7 to 84.3; 95% CI, 25.1 to 86.3). The vac-
cine efficacy among participants who met the 
criteria for the second case definition was 61.7% 
(90% CI, 24.1 to 80.6; 95% CI, 13.5 to 83.0). 
Among participants who met the criteria for the 
other protocol-specified case definitions, the ef-
ficacy ranged from 29.5 to 40.3% (Table 1).
Analyses performed in the total efficacy co-
hort yielded results that were similar to those in 
the according-to-protocol efficacy cohort. In the 
total efficacy cohort, the incidence of pulmonary 
Covariate and Group
No. of Participants/ 
Total No.†
Person-yr of  
Follow-up
Rate per 100  
Person-yr (90% CI) Vaccine Efficacy
% (90% CI) % (95% CI)
BCG vaccination§
No
M72/AS01E 1/136 372.22 0.3 (0.1 to 1.4) Undefined Undefined
Placebo 0/149 402.43 0
Yes
M72/AS01E 10/1244 3382.25 0.3 (0.2 to 0.5) 52.8 (11.3 to 74.9) 52.8 (−0.1 to 77.8)
Placebo 21/1250 3358.44 0.6 (0.4 to 0.9)
Unknown
M72/AS01E 2/245 670.43 0.3 (0.1 to 1.0) 58.1 (−65.9 to 89.4) 58.1 (−115.9 to 91.9)
Placebo 5/264 702.18 0.7 (0.3 to 1.5)
Baseline QFT level  
— IU/ml‡¶
<4
M72/AS01E 5/692 1886.81 0.3 (0.1 to 0.6) 56.2 (−6.4 to 82) 56.2 (−26.1 to 84.8)
Placebo 11/680 1820.62 0.6 (0.4 to 1.0)
≥4
M72/AS01E 8/934 2540.81 0.3 (0.2 to 0.6) 44.7 (−13.7 to 73.1) 44.7 (−30.5 to 76.5)
Placebo 15/983 2642.44 0.6 (0.4 to 0.9)
Body-mass index‡‖
≤25
M72/AS01E 12/1130 3057.08 0.4 (0.2 to 0.6) 42.1 (−5.6 to 68.2) 42.1 (−18.5 to 71.7)
Placebo 20/1113 2960.81 0.7 (0.5 to 1.0)
>25
M72/AS01E 1/495 1367.67 0.1 (0.0 to 0.4) 81.8 (−7.6 to 96.9) 81.8 (−51.2 to 97.8)
Placebo 6/546 1491.10 0.4 (0.2 to 0.8)
*  The analysis was conducted with an unadjusted Cox regression model in the according-to-protocol efficacy cohort.
†  Shown is the number of participants who met the criteria for the first case definition and the total number of participants.
‡  The analysis was a post hoc analysis.
§  Bacille Calmette–Guérin (BCG) vaccination indicates documentation of previous BCG vaccination or the presence of a BCG scar.
¶  QFT denotes QuantiFERON-TB Gold In-Tube assay.
‖  The body-mass index is the weight in kilograms divided by the square of the height in meters.
Table 2. (Continued.)
The New England Journal of Medicine 
Downloaded from nejm.org at LONDON SCH HYGIENE & TROPICAL MED on November 1, 2019. For personal use only. No other uses without permission. 
 Copyright © 2019 Massachusetts Medical Society. All rights reserved. 
n engl j med nejm.org 8
T h e  n e w  e ngl a nd  j o u r na l  o f  m e dic i n e
tuberculosis that met the first case definition was 
0.3 cases per 100 person-years in the M72/AS01E 
group and 0.6 cases per 100 person-years in the 
placebo group, and the vaccine efficacy was 54.1% 
(90% CI, 20.3 to 73.6; 95% CI, 11.5 to 76.2) 
(Table 1).
Results of prespecified subgroup analyses 
among participants who met the criteria for the 
first case definition indicated a higher vaccine 
efficacy among participants who were 25 years 
of age or younger than among participants who 
were older than 25 years of age (vaccine efficacy, 
81.1% vs. −0.6%) and showed a significant inter-
action for the difference between the age groups 
(P = 0.02, unadjusted for multiplicity) (Table 2). 
However, the age distribution among participants 
who had tuberculosis cases that met the first 
case definition was unevenly clustered around 
the cutoff of 25 years (Fig. 2). When we repeated 
the subgroup analysis with an age cutoff above 
that cluster (i.e., 30 years), we observed a vaccine 
efficacy of 50.0% (90% CI, 2.2 to 74.5; 95% CI, 
−11.3 to 77.5) among participants 30 years of 
age or younger and 49.0% (90% CI, −39.7 to 
81.4; 95% CI, −69.4 to 84.6) among participants 
older than 30 years of age (Table 2). In addition, 
a post hoc analysis did not show a significant in-
teraction between age as a continuous variable and 
group assignment with respect to efficacy. The 
distribution of QFT levels in positive and negative 
cases of tuberculosis is provided in Figure S2.
Immunogenicity
The according-to-protocol immunogenicity cohort 
included 244 participants (120 in the M72/AS01E 
group and 124 in the placebo group) (Table S4). 
All participants in this cohort were from Kenya 
or South Africa, and the demographic character-
istics were similar to those of the total vacci-
nated cohort. All participants in the M72/AS01E 
group were seropositive by month 2 and remained 
positive until month 36 (Fig. 3A). Results of post 
hoc analyses of the geometric mean concentra-
tions of anti-M72 IgG antibodies (stratified ac-
cording to sex, baseline QFT level [<4 IU per 
milliliter or ≥4 IU per milliliter], age [≤25 years or 
>25 years], and country [Kenya or South Africa]) 
are shown in Figure S3. All 95% confidence in-
tervals overlap between groups, with the excep-
tion of the geometric mean concentration of anti-
M72 IgG antibodies among participants in South 
Africa (670.9 ELISA units per milliliter; 95% CI, 
Figure 2. Tuberculosis Cases According to Age at Enrollment (According-to-
Protocol Efficacy Cohort).
Shown is a post hoc assessment of the distribution of the 39 cases of tuber-
culosis that met the first case definition, according to the age of the participant.
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Figure 3 (facing page). Immunogenicity Analyses.
Immunogenicity was assessed in the according-to-pro-
tocol immunogenicity cohort (120 participants in the 
M72/AS01E group and 124 participants in the placebo 
group) from the time of randomization (before the first 
dose of M72/AS01E or placebo) until month 36. Poly-
positive CD4+ T cells were defined as those that ex-
pressed at least two immune markers (interferon-γ, 
 interleukin-2, tumor necrosis factor α [TNF-α], or 
CD40L). Panel A shows the geometric mean concen-
trations of anti-M72 IgG antibodies in the M72/AS01E 
group and the placebo group in enzyme-linked immu-
nosorbent assay (ELISA) units per milliliter. The dashed 
line indicates the assay cutoff to determine seropositiv-
ity. For descriptive purposes, all participants who had 
a value below the assay cutoff were assigned a value of 
half the cutoff. I bars indicate 95% confidence intervals. 
Panel B shows the median frequencies of M72-specific 
CD4+ T cells in the two groups according to expression 
of immune markers and month. Panel C shows the me-
dian frequencies of M72-specific CD4+ T cells express-
ing any one or any combination of immune markers 
among participants in the M72/AS01E group. The I bars 
indicate the interquartile range. Panel D shows the me-
dian frequencies of polypositive M72-specific CD4+  
T cells according to country (post hoc analysis). Panel E 
shows the median frequencies of M72-specific CD4+  
T cells expressing interferon-γ overall and according to 
country (post hoc analysis). Q1 denotes the first quartile, 
and Q3 the third quartile.
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527.9 to 852.5) and Kenya (440.4 ELISA units per 
milliliter; 95% CI, 375.2 to 516.8) at month 2.
Among participants in the M72/AS01E group, 
the frequencies of polypositive M72-specific CD4+ 
T cells increased substantially after administra-
tion of the vaccine and persisted through month 
36, with no evidence of waning (Fig. 3B). Poly-
positive M72-specific CD4+ T cells predominantly 
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expressed interferon-γ, interleukin-2, or TNF-α, 
or any combination of the three, and CD40L 
expression was low at all time points (Fig. 3C). 
The percentage of participants with a response 
to the vaccine was 23.5% (95% CI, 12.8 to 37.5) 
at month 2 and 53.7% (95% CI, 39.6 to 67.4) at 
month 36.
The frequencies of polypositive M72-specific 
CD4+ T cells were lower at month 2 than at sub-
sequent time points, with a wide interquartile 
range (Fig. 3B) that coincided with a peak of 
T cells expressing only interferon-γ (Fig. 3C). 
The frequency of polypositive T cells was ap-
proximately 5 times as high among participants 
in Kenya as among those in South Africa (median 
at month 2, 2636.0 vs. 529.0 per million CD4+ 
T cells) (Fig. 3D), whereas there was little differ-
ence between the two countries in the frequen-
cies of T cells that expressed interferon-γ alone 
or interferon-γ in addition to other immune 
markers (Fig. 3E). The median frequencies of CD4+ 
T cells at month 2 that expressed interferon-γ 
alone were 1134.0 and 450.0 per million CD4+ 
T cells in South Africa and Kenya, respectively. 
Results of a post hoc analysis of the frequency 
of M72-specific CD4+ T cells expressing inter-
feron-γ alone or interferon-γ in addition to other 
immune markers at month 2 — stratified ac-
cording to sex, QFT level at baseline (<4 IU per 
milliliter or ≥4 IU per milliliter), and age (≤25 
years or >25 years) — showed no obvious differ-
ences among these subgroups (Fig. S4).
There was no significant change in polypositive 
M72-specific CD4+ T-cell frequencies after admin-
istration of placebo at any time point. No CD8+ 
T-cell responses could be detected in either group.
Safety
Two serious adverse events were considered by 
the investigators to be related to the trial regi-
men: one case of pyrexia in the M72/AS01E group 
(with onset on the day of dose 2) and one case 
of hypertensive encephalopathy in the placebo 
group (with onset on the day of dose 1). There 
were 47 deaths during the trial period: 19 deaths 
among 1786 participants (1.1%) in the M72/AS01E 
group and 28 among 1787 participants (1.6%) in 
the placebo group (relative risk, 0.68; 95% CI, 
0.36 to 1.26; P = 0.24). No deaths were deter-
mined by the investigators to be related to the 
trial regimen. The most common cause of death 
was trauma (in 28 participants). (All serious 
adverse events reported until month 6 after the 
second dose are listed in Table S5, all serious 
adverse events reported throughout the entire 
trial period in Table S6, and all deaths in Table 
S7.) Potential immune-mediated diseases were 
reported in 2 participants in the M72/AS01E 
group and in 6 in the placebo group and af-
fected a variety of organ classes (Table S8).
Discussion
The adjuvanted recombinant protein vaccine 
M72/AS01E, which contains two M. tuberculosis 
antigens, provided approximately 50% protection 
against progression to active pulmonary tuber-
culosis for 3 years in M. tuberculosis–infected, 
HIV-negative adults. This protection was observed 
among participants who met the criteria for the 
first and second case definitions and was also 
observed in the sensitivity analysis. These results 
support further evaluation of M72/AS01E as a tool 
for global tuberculosis control and represent 
progress toward a vaccine that meets the attri-
butes recommended by the WHO for new tuber-
culosis vaccines targeted at adolescents and 
adults.3
In our previous report, an exploratory sub-
group analysis indicated higher percentage esti-
mates for vaccine efficacy among participants 25 
years of age or younger than among participants 
older than 25 years of age.5 Although this result 
is still apparent in the final analysis, graphical 
representation of the distribution of tuberculosis 
cases according to age at enrollment reveals 
clustering between 23 and 27 years and suggests 
that the result is a chance finding (Fig. 2). A post 
hoc analysis that used age as a continuous vari-
able did not suggest any age effect on vaccine 
efficacy. Our final data set does not support the 
hypothesis of differential vaccine efficacy accord-
ing to age. Similarly, other covariates, such as sex, 
were not associated with differences in vaccine 
efficacy in exploratory interaction tests (Table 2).
Humoral responses were consistent with pre-
vious experience with M72/AS01E,
8-11 and the re-
sponses were sustained until month 36. The 
persistence of humoral and polypositive cellular 
responses is noteworthy. These results were gen-
erated from a limited subgroup of participants 
in whom no cases of tuberculosis occurred, and 
no analysis of associations between the immune 
response and protection can be made. However, 
The New England Journal of Medicine 
Downloaded from nejm.org at LONDON SCH HYGIENE & TROPICAL MED on November 1, 2019. For personal use only. No other uses without permission. 
 Copyright © 2019 Massachusetts Medical Society. All rights reserved. 
n engl j med nejm.org 11
Trial of M72/AS01E Vaccine to Prevent Tuberculosis
the majority of participants consented to bio-
banking of blood specimens for evaluation in a 
substudy to discover potential immune corre-
lates of risk or protection (ClinicalTrials.gov num-
ber, NCT02097095).
We observed lower-than-expected frequencies 
of polypositive CD4+ T cells at month 2. This 
was attributable largely to the CD4+ T-cell re-
sponses among participants in South Africa, 
whose CD4+ T-cell responses were characterized 
by an almost exclusive expression of interferon-γ 
at month 2 (with no detectable expression of 
CD40L), and so were not captured within the 
polypositive T-cell population. This observation 
of lower-than-expected frequencies of polyposi-
tive CD4+ T cells at month 2 is reflected in the 
overall response rate of 23.5% at that time point. 
We believe this response rate is artificially low 
because of the conservative definition of a re-
sponse (a polypositive T-cell frequency higher 
than the 95th percentile of the frequencies in 
all participants before administration of the first 
dose), and this result contrasts with the 100% 
seropositivity rate for anti-M72 antibodies at 
month 2.
By month 12, the cells that had been express-
ing only interferon-γ had been replaced by cells 
with polypositive profiles. This predominance 
of CD4+ T cells producing only interferon-γ at 
month 2 was not observed in previous analyses 
involving South African participants.8,9 In-depth 
analysis of quality controls did not identify tech-
nical problems during collection, processing, or 
testing of samples obtained at month 2. Although 
we cannot exclude the possibility of a technical 
artifact, the different patterns of CD4+ T-cell 
expression observed between participants in 
Kenya and those in South Africa may correspond 
to various states of cellular differentiation result-
ing from a combination of infection-related 
factors, vaccine-induced factors, and ethnic-group 
factors.
In previous studies, M72-specific CD8+ T-cell 
responses were detected at low levels in blood 
samples obtained 7 days after the first immuni-
zation.8,9 This time point was not included in the 
analyses in the current trial, and therefore we do 
not know whether CD8+ T-cell responses have a 
role in protection.
The findings during the extended follow-up 
are consistent with the previously reported safety 
profile of M72/AS01E. No patterns were evident 
with respect to the occurrence or the nature of 
serious adverse events, fatal events, or potential 
immune-mediated diseases over the trial period.
These results show that vaccine efficacy of 
M72/AS01E against pulmonary tuberculosis and 
vaccine-induced immune responses were sus-
tained for 3 years. These results need confirma-
tion in larger and longer studies conducted in a 
broader range of populations, including persons 
who have negative results on interferon-γ release 
assay, who are of various ethnic backgrounds, 
who live in various geographic locations, and 
who are of various age groups.
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